Search the Newsreel

Spruce (SPRB) Q2 2026 Earnings: The Bottom-Line Figure Trails Its Comparison in the Latest Session; Reaction Snapshot: Shares Finish 0.14% Lower in the Current Update - Non-GAAP Earnings

Will BridgeBio’s (BBIO) US$390 Million Raise and Late‑Stage Pipeline Progress Change Its Narrative?

BridgeBio Pharma, Inc. recently completed a US$390 million equity offering and reported Q2 2026 revenues of US$243.68 million with a net loss of US$152.22 million. The company also highlighted new clinical data for Attruby and advanced its rare-disease pipeline with regulatory progress for BBP-418 …

PRCT DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRCT

The Rosen Law Firm is reminding purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock during the Class Period (February 28, 2024, and February 25, 2026) of an important lead plaintiff deadline of September 22, 2026. The lawsuit alleges that PROCEPT made materially false …

Pacific Biosciences CEO Mark van Oene sells $30,409 in stock

Pacific Biosciences CEO Mark van Oene sold 26,911 shares of company stock for $30,409 on August 17, 2026. This transaction was primarily to cover tax withholding obligations associated with the vesting of restricted stock units. The sale occurred as PACB stock trades near its …

Legend (LEGN) Quarterly Update: EPS Exceeds Its Estimate in Latest Trading; Shares After the Report: The Market Price Advances 6.15% in the Latest Session - Revenue Recognition Risk

Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 26,911 Shares of Stock

Pacific Biosciences of California (NASDAQ:PACB) insider Oene Mark Van sold 26,911 shares of the company's stock for approximately $30,409. The sale was primarily to cover tax withholding obligations related to vested equity awards, reducing his holdings by 0.98%. This transaction occurred as PACB shares …

Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data

Neurocrine Biosciences (NBIX) is potentially 28% undervalued according to a recent analysis, following positive KINECT-PRO Phase 4 results for its drug INGREZZA. Despite a recent share price dip, NBIX has shown strong long-term returns and has a diverse CNS pipeline, suggesting significant future growth …

Twist (TWST) EPS and Revenue Review: The Bottom-Line Figure Trails Its Comparison in the Current Update; Session Reaction: The Stock Ends Down 6.68% in the Available Record - Post-Earnings Drift

Emergent BioSolutions Balances Q2 Beat With Tough Outlook

Emergent BioSolutions reported strong Q2 financial results, exceeding revenue and profitability expectations primarily due to accelerated medical countermeasure deliveries. However, the company faces significant challenges in its naloxone franchise, leading to a substantial noncash impairment charge, lower full-year revenue and profitability guidance for 2026, …

Skye Bioscience (SKYE) holder sells shares, funds Redx merger

5AM-affiliated funds and individuals have updated their beneficial ownership in Skye Bioscience (SKYE) and detailed a strategic merger with Redx Pharma Limited. Skye will acquire Redx shares through a UK Scheme of Arrangement, with Redx pre-transaction equity holders expected to own 46.17% of the …

PacBio (NASDAQ: PACB) CEO share sale covers RSU tax withholding

PacBio (NASDAQ: PACB) CEO Mark Van Oene sold 26,911 shares of common stock on August 17, 2026, at a weighted average price between $1.13 and $1.15 per share. This sale was automatically conducted to cover tax withholding obligations associated with the vesting of restricted …

Quantum (QNTM) Results Breakdown: The Latest Report Adds New Financial Reference Points under the Current Snapshot; Post-Earnings Trading: The Stock Records a 9.24% Decrease on the Day - Guidance Revision Trend

Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock

Pacira BioSciences insider Jonathan Slonin sold 3,040 shares of the company's stock for a total of $70,619.20. This transaction reduced his ownership by 1.39% to 216,384 shares and was executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock traded up 3.3% to …

First Tracks Biotherapeutics CBO Benjamin Stone Receives 60,492 Performance Stock Units

Benjamin Stone, Chief Business Officer of First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX), was granted 60,492 performance stock units (PSUs) on August 15, 2026. This grant followed the certification of performance goals by the Compensation Committee. The PSUs will vest in two equal installments on …

Arcutis (ARQT) Q2 2026 Earnings: EPS Beats Its Estimate in Latest Trading; Shares After the Report: The Stock Ends Up 3.63% at the Close - Segment Revenue Breakdown

Can Sana Biotechnology (SANA) Justify Its Valuation On Narrower Losses?

Sana Biotechnology (SANA) recently reported narrower net losses for Q2 and H1 2026, leading to a recent positive shift in share price momentum. However, the company's Price-to-Book (P/B) ratio of 7x is significantly higher than the industry average, suggesting an overvalued status. Investors are …

BioXcel Therapeutics Faces August 21 Oaktree Transaction Deadline As $13.8 Million Cash Funds Operations Only Through August

BioXcel Therapeutics is facing an August 21 deadline to secure an acceptable transaction with its Oaktree-affiliated lenders, as its current cash reserves of $13.8 million are only sufficient to fund operations through August 2026. The company has severe liquidity issues, negative working capital, and …

BIO-TECHNE Executive Steven C. Crouse Files Form 4 After RSU Vesting and Share Withholding

Steven C. Crouse, President of Diagnostics and Spatial Biology at BIO-TECHNE Corp (NASDAQ:TECH), filed a Form 4 detailing stock transactions on August 18, 2026. The filing reported the vesting of 5,423 restricted stock units (RSUs) and the withholding of 1,947 shares at $72.4 per …

Orchestra (OBIO) Reported Results Review: EPS Prints Above Forecast for the Current Session; Price Action: Shares Close 19.92% Higher at the Close - Profit Recovery Report

Zenas BioPharma (ZBIO) Looks Pricey Following Weak Q2 Results And Leadership Changes

Procept BioRobotics CEO Buys 23,900 Shares Amid 48% Stock Decline. What Does This Tell Investors?

Larry L. Wood, the President and CEO of Procept BioRobotics Corporation (NASDAQ:PRCT), reported an indirect purchase of 23,900 shares of common stock on August 7, 2026. SEC Form 4 filing. Transaction summary Metric Value Transaction value ~$498,000 Post-transaction value $6.9 million Post-transaction shares (directly …

BridgeBio (NASDAQ: BBIO) CEO has 71K RSUs vest, withholds shares for taxes

BridgeBio Pharma, Inc. CEO Neil Kumar had 71,217 Restricted Stock Units (RSUs) convert into common stock on August 16, 2026. To cover tax obligations from this vesting, 36,237 shares were withheld at $79.86 per share. Following these transactions, Kumar's indirect holdings across various trusts …

Adaptive Biotechnologies (NASDAQ: ADPT) director plans to resell 30,664 shares

Adaptive Biotechnologies (ADPT) director Robert M. Hershberg has filed a Form 144 notice to potentially resell up to 30,664 shares of common stock. The proposed sale has an aggregate market value of $748,303.36 and includes shares from a stock option exercise and restricted stock. …

Price to earnings forward of Beijing Luzhu Biotechnology Co., Ltd. Class H – HKEX:2480

Q32 (QTTB) Earnings Check: The Available Earnings Metric Delivers a Beat in the Latest Session; Reaction Snapshot: Shares Fall 4.14% in the Available Record - Geographic Revenue Trends

Biocon Limited Actuals & Estimates (NSE:BIOCON)

Barinthus (BRNS) Earnings Check: EPS Exceeds Its Estimate in the Current Update; The Market Price Advances 4.47% at the Close - EBITDA Margin Trends

Barinthus (BRNS) Earnings Check: EPS Exceeds Its Estimate in the Current Update; The Market Price Advances 4.47% at the Close - Profit Inflection Point

Bio-Techne (TECH) CEO exercises awards, 10.8K shares withheld

Bio-Techne CEO Kim Kelderman reported multiple equity award updates on August 15, 2026, acquiring 21,470 shares of common stock through exercises while 10,821 shares were withheld for tax and exercise costs. The Board authorized discretionary vesting for certain performance restricted stock units and options, …

Bio-Techne (TECH) CFO exercises awards, covers taxes in stock

Bio-Techne (TECH) CFO James Hippel reported equity-award transactions on August 15, 2026, acquiring 9,779 common shares through restricted stock unit exercises and having 4,310 shares withheld at $72.40 for tax liabilities. The board also authorized discretionary vesting for 866 performance RSUs and 2,332 performance …

Bio-Techne (NASDAQ: TECH) exec updates option and RSU holdings

William Geist, President of Protein Sciences at Bio-Techne Corp (TECH), has reported 13 insider transactions involving grants of restricted stock units. The Form 4 filing details direct holdings including 44,596 Restricted Stock Units, 123,059 Stock Options (Right to Buy), 35,093 Performance Restricted Stock Units, …

ETFs Investing in Fortress Biotech, Inc. Stocks

This article lists ETFs that include Fortress Biotech, Inc. (FBIO) stocks, highlighting how these funds make investing in stocks more accessible and potentially lower risk. It provides a table with details on two such ETFs: iShares Microcap ETF (IWC) and EA Bridgeway Omni Small-Cap …

Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan

Pacira BioSciences (PCRX) Chief Medical Officer, Jonathan Slonin, sold 3,040 shares of common stock on August 17, 2026, at $23.23 per share through an open-market transaction. This sale was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025. Following the transaction, …

Biogen Inc. stock underperforms Tuesday when compared to competitors despite daily gains

Shares of Biogen Inc. (BIIB) rose 1.63% on Tuesday to $212.55, breaking a two-day losing streak, despite a generally grim trading session for the broader stock market. The S&P 500 Index fell 0.69% and the Dow Jones Industrial Average declined 0.22%. Despite its daily …

BioMarin looks to spur growth with potential $490M buyout of Dutch bone drug company

BioMarin Pharmaceutical is reportedly looking to acquire Dutch bone drug company Alesa Therapeutics for up to $490 million, including a $275 million upfront payment. This potential acquisition comes shortly after BioMarin decided to halt the late-stage development of another drug. The move is seen …

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

Sabrina Martucci Johnson, CEO of Daré Bioscience, has been recognized on Forbes' 2026 “50 Over 50: Innovation” list for her significant impact in women's health. The company, founded in 2015, is evolving from a clinical-stage biotechnology firm to a multi-product women's health company with …